ClinicaliQ Trial Snapshot
- Study of INBRX-109 in Conventional Chondrosarcoma — Active Not Recruiting • Phase II • NCT04950075.
- Experimental drug INBRX-109 tested against placebo in patients with advanced chondrosarcoma that cannot be surgically removed.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients. Conditions: Conventional Chondrosarcoma Interventions: INBRX-109, Placebo Lead Sponsor: Inhibrx Biosciences, Inc Planned Enrollment: 206 participants